Antioxidant protection and prostatic disease;Protezione antiossidante e patologie prostatiche

Trends in Medicine

Volumn 9, Issue 4, 2009, Pages 179-186

  Morgia, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antioxidants; Oncoprevention; Prostate cancer; Prostatic diseases; Prostatitis

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CYTOKINE; DNA; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; LYCOPENE; REACTIVE OXYGEN METABOLITE; SELENIUM; SOMATOMEDIN C; TRACE ELEMENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; XANTHOPHYLL; ZINC;

APOPTOSIS; CANCER PREVENTION; CANCER RISK; CELL CYCLE; DIET SUPPLEMENTATION; DIETARY INTAKE; FAT INTAKE; HEALTH PROMOTION; HUMAN; MALE; OXIDATIVE STRESS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; TEA; VITAMIN INTAKE;

EID: 75749156632     PISSN: 15942848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Davis JN, Day ML. The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis. Mol Biotechnol 2002; 22:129-138.
2. Kambhampati S, Ray G, Sengupta K, et al. Growth factors involved in prostate carcinogenesis. Front Biosci 2005; 10:1355-1367.
3. Pathak SK, Sharma RA, Steward WP, et al. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer. 2005;41:61-70.
4. Klein EA, Casey G, Silverman R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006; 68:1145-1151.
5. Minelli A, Bellezza I, Conte C, et al. Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta 2009; 1795:83-91.
6. Lou JG, Dong J, Zheng YC, et al. Increased oxidative stress and damage in patients with chronic bacterial prostatitis. Biomed Environ Sci 2006; 19:481-486.
7. Aydin A, Arsova-Sarafinovska Z, Sayal A, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006; 39:176-179.
8. Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol 2008; 6:29-36.
9. Platz EA, Helzlsouer KJ. Selenium, zinc, and prostate cancer. Epidemiol Rev 2001; 23:93-101.
10. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med 2002; 227: 920-923.
11. Bostwick DG, Cooner WH, Denis L, et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70(1 Suppl):291-301.
12. Ornstein DK, Rao GS, Smith DS, et al. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157:880-883.
13. Schwarz S, Obermüller-Jevic UC, Hellmis E, et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008; 138:49-53.
14. Calò LA, Pagnin E, Davis PA, et al. Effect of doxazosin on oxidative stress-related proteins in benign prostatic hyperplasia. Urol Int 2006; 76:36-41.
15. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995; 87:1767-76
16. Jian Le, Du Chuan-Jun, Lee HA et al. Do dietary lycopene protect against prostate cancer? Int J Canc 2005; 113:1010-1014.
17. Sun SL, He GQ, Yu HN, et al. Free Zn(2+) enhances inhibitory effects of EGCG on the growth of PC-3 cells. Mol Nutr Food Res 2008; 52:465-471.
18. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutr 2001; 4:593-599.
19. Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Canc 2003; 103:664-670.
20. Mucci LA, Temimi R, Lagiou P, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001; 87: 814-820.
21. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15:841-849.
22. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009; 124:2416-2429.
23. Nahum A, Zeller L, Danilenko M, et al. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 2006; 45:275-282.
24. Liu X, Allen JD, Arnold JT, Blackman MR. Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in cocultured reactive stromal cells. Carcinogenesis 2008; 29:816-823.
25. Clinton SK. The dietary antioxidant network and prostate carcinoma. Cancer 1999; 86:1629-1631.
26. Yilmaz MI, Saglam K, Sonmez A, et al. Antioxidant system activation in prostate cancer. Biol Trace Elem Res 2004; 98:13-19.
27. Stuart EC, Scandlyn MJ, Rosengren RJ. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 2006; 79:2329-2336.
28. Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5:371-373.
29. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 2008; 19:848-855.
30. Gupta S, Ahmad N, Nieminen AL. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent(-)- epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164:82-90.
31. Rettig MB, Heber D, An J, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 2008; 7:2662-2671.
32. Chen X, Yu H, Shen S, Yin J. Role of Zn2+ in epigallocatechin gallate affecting the growth of PC-3 cells. J Trace Elem Med Biol 2007; 21:125-131.
33. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81:730-734.
34. Duffield-Lillico AJ, Dalkin BL, Reid ME; Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91:608-612.
35. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
36. Mawson CA, Fisher MI. The occurrence of zinc in the human prostate gland. Can J Med Sci 1952; 30:336-339.
37. Golovine K, Uzzo RG, Makhov P, et al. Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. Prostate 2008; 68:1443-1449.
38. Killilea AN, Downing KH, Killilea DW. Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells. Cancer Lett 2007; 258:70-79.
39. Chan R, Lok K, Woo J. Prostate cancer and vegetable consumption. Mol Nutr Food Res 2009; 53:201-216.
40. Kirsh VA, Peters U, Mayne ST, et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 2007; 99:1200-1209.
41. Drasch G, Schöpfer J, Schrauzer GN. Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 2005;103:103-107.
42. Krishnadasan A, Kennedy N, Zhao Y, et al. Nested case-control study of occupational chemical exposures and prostate cancer in aerospace and radiation workers. Am J Ind Med 2007; 50:383-390.
43. Simůnek T, Stérba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61:154-171.
44. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005; 4:110-130.
45. Li W, Xu B, Xu J, Wu XL. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. Basic Clin Pharmacol Toxicol 2009; 104:192-197.
46. Lu JP, Monardo L, Bryskin I, et al. Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis 2009 Jun 23. [Epub ahead of print]